Algotec adds OEM partnersAlgotec has broadened its distribution channels with the signing of several OEM agreements. The Raanana, Israel-based firm has announced that Atlanta-based HIS firm Eclipsys has chosen Algotec as its joint medical
Algotec has broadened its distribution channels with the signing of several OEM agreements. The Raanana, Israel-based firm has announced that Atlanta-based HIS firm Eclipsys has chosen Algotec as its joint medical imaging marketing partner. Another company, North American Imaging of Caramilla, CA, will purchase and distribute Algotec's ProVision workstation and MediSurf Java applet-based Web browser image management software. Finally, Bio-Imaging Technologies of Trenton, NJ, will be using ProVision in clinical drug studies for new drug development.
Applicare Medical Imaging
P.O. Box 936
3700 AX Zeist
The Netherlands
31 (0) 30 6926000
Fax.: +31 (0) 30 6926010
www.applicare.comsales@applicare.com
Product line
Key personnel
Number of employees
Product distribution
Revenues
Key installations
Long-term strategy
Applicare believes its emphasis on Windows NT has been a key factor in the company's success, and the firm will continue to base its PACS software on the Microsoft platform. The company would like to make its viewing software broadly available throughout the PACS market, and as such, is looking to secure additional OEM distribution agreements for RadWorks.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.